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A commentary on
Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile
infection is associated with treatment outcome
by Zuo T., Wong S. H., Lam K., Lui R., Cheung K., Tang W., et al. (2017). Gut 67, 634–643.
doi: 10.1136/gutjnl-2017-313952
Fecal microbiota transplantation (FMT) has been used as a treatmentof last resort for recurrent
C. difficile infections (CDI) with a cure rate of 85–90% after the first FMT (van Nood et al., 2013;
Jiang et al., 2017). Several studies have examined the changes that occur in the bacterial community
that leads to reestablishment of the intestinal microbiota (Fuentes et al., 2014; Seekatz et al., 2014;
Staley et al., 2016). However, studies that have investigated the role of viruses in FMT are limited
(Broecker et al., 2016a,b, 2017; Ott et al., 2017).
Recently, Zuo and colleagues performed metagenomics sequencing of virus like particles on
fecal samples from patients with CDI and healthy controls to determine if bacteriophages were
associated with restoration of the intestinal microbiota after FMT (Zuo et al., 2017). Prior to
FMT, the patients had increased abundance of Caudovirales with decreased diversity, richness and
evenness when compared to healthy controls. Longitudinal studies of patients who received FMT
(n = 9) and standard therapy, vancomycin (n = 5) demonstrated that FMT led to the transfer of
viruses from the donor to the recipients (Zuo et al., 2017).
The patients that were administered FMT were divided into two groups of “responders” and
“non-responders” based on whether they were cured of CDI or recurred after FMT. In particular,
after FMT, they noticed a significant decrease in the abundance of Caudovirales and increase in
richness of donor-derived Caudovirales in the enteric virome of the patients (Zuo et al., 2017).
There was a correlation between donor viral richness and the patients responding to FMT. Of the
two-thirds that were cured after FMT, four of the donors had higher Caudovirales richness when
compared to the non-responders group where the donor Caudovirales richness was lower (Zuo
et al., 2017).When compared to the non-responders, the remaining two donors had a similar (n= 1
for non-responder donor) or slightly higher Caudovirale richness.
Furthermore, lower abundance of the family, Microviridae was observed in the patients before
FMT when compared to the controls but this increased after FMT. Fifteen viral species were
found to be enriched between FMT responders and non-responders. Viral species belonging to the
Microviridae family such as Eel River Basin pequenovirus was the most abundant in the responders
(Zuo et al., 2017).
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Moreover, Zuo et al. performed 16S rRNA gene sequencing
to determine changes in the bacterial community and noted
increase in Lachnospiraceae and Ruminococcaceae families (Zuo
et al., 2017). However, there was no significant difference
between donor transferred bacteria between FMT responders
and non-responders. Interestingly, vancomycin treatment had
no significant effect on the viral community (Caudovirales)
of those who responded to the antibiotic therapy. However,
the bacterial community was significantly affected (Zuo et al.,
2017).
Broecker et al. investigated the long term bacterial and
virome changes in a patient after FMT for recurrent CDI,
and found the virome at several months post-FMT related
to the donor virome (Broecker et al., 2016a,b). Similarly,
Ott and colleagues recently demonstrated that sterile
fecal filtrates from donor feces was effective in treating
recurrent CDI in five patients (Ott et al., 2017). They
showed that the “phagebiota” of a recipient at 6 weeks
post-FMT was similar to the fecal filtrate from the donor
(Ott et al., 2017). These findings indicate that apart from
live bacteria, other components of the microbiota such as
bacteriophages, antimicrobial compounds or metabolites
contribute to reestablishment of the intestinal microbiota
in FMT.
There is no doubt that bacteriophages play a role in the
intestinal microbiota with a potential to alter the composition
and function of the host microbiota. The question is what
constitutes a healthy gut phageome and how do they influence
the human gut microbiota? Most of the phages in healthy
human gut microbiota belong to the Caudovirales order
and from the family Microviridae which have double and
single stranded DNA respectively (Kim et al., 2011; Manrique
et al., 2016). As seen above in recurrent CDI, increased
diversity, richness and evenness of the Caudovirales was
implicated in the efficacy of FMT. However, in other intestinal
diseases, it is not clear cut as to the role of Caudovirales
likely due to other risk factors involved (Norman et al.,
2015). For example, Caudovirales richness was observed in
patients with inflammatory bowel disease (Norman et al.,
2015).
The next question one may be tempted to ask is, how stable
is the “phagebiota” in individuals and what are the effects
of antibiotic perturbations on the phageome? Research by Ly
et al. showed that transmission of viruses was common between
members of the same household over a 6-month period (Ly et al.,
2016). Treatment of healthy individuals living in a particular
household with the antibiotics, amoxicillin or azithromycin for
7 days did not affect the composition of viruses in the intestinal
microbiota (Ly et al., 2016).
These studies have highlighted the underappreciated role
viruses play in addition to bacterial colonization in the intestinal
microbiota. However, as individual phages are specific in action
toward their bacterial host, it would be advantageous to isolate
phages that target pathogenic bacteria such as C. difficile,
though this is not trivial. Indeed, previous work revealed that
using a single phage, 8CD27 (Meader et al., 2010, 2013) or a
combination of phages led to the inhibition of C. difficile growth
in vitro and in vivo (Nale et al., 2016a,b). Recently, a combination
of four phages was found to totally inhibit C. difficile growth in
a batch fermentation model spiked with feces from four healthy
volunteers (Nale et al., 2018).
Much work remains to be done on phage therapy for
C. difficile infection. The ability to develop a synthetic mixture of
phages as treatment for infectious diseases, will go a long way in
this era of antibiotic resistance. Not only will this be beneficial in
severe CDI, but could also be useful as a therapy for other diseases
related to the intestinal microbiota.
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